Skip to main content

Table 2 Crude association between hepatic adverse events and episodes groups over treatment arms

From: Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

Episodes groups COR (95% CI) with hepatic adverse events
Elevated ALT Elevated AST Elevated ALP Elevated direct bilirubin Elevated total bilirubin
AL First treatment 1 1 1 1 1
Retreatment 0.25
(0.08; 0.72) *
0.18
(0.07;0.45) ***
2.09
(0.58; 7.58)
1.80
(0.99; 3.30)
2.13
(1.15; 3.92) *
PA First treatment 1 1 1 1 1
Retreatment 0.33
(0.14; 0.76) *
0.65
(0.28; 1.53)
1.17
(0.33; 4.04)
1.66
(0.83; 3.34)
1.36
(0.71; 2.60)
  1. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; p: p-value; SD: Standard deviation; COR: crude odds ratio; CI: Confidence interval; AL: artemether–lumefantrine; PA: pyronaridine-artesunate
  2. * p < 0.05
  3. ** p < 0.01
  4. *** p < 0.001